Loading company
Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Biocryst Pharmaceuticals, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
BCRX · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$7.61-0.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $625M to $645M for Fiscal year 2026 — down 27.4% on a year earlier ($874.8M)